DRUG-INDUCED AUTOIMMUNE-LIKE HEPATITIS AND CHOLELITHIASIS ASSOCIATED WITH DULAGLUTIDE AND SEMAGLUTIDE USE IN A YOUNG ADULT: A CASE REPORT AND REVIEW OF LITERATURE
Main Article Content
Keywords
glp-1 receptor agonists, semaglutide, hepatitis, cholelithiasis, dulaglutide
Abstract
Only few cases of liver injury induced by liraglutide (glucagon-like peptide-1 receptor agonist) with complete recovery after drug discontinuation and administration of corticosteroid have been reported. This report presents the case of a 29-year-old Saudi female patient who presented to the emergency department complaining of acute right upper quadrant abdominal pain for three days. She was an occasional smoker for the past 10 years with no relevant medical or surgical history. The young female developed autoimmune-like hepatitis due to the intake of Dulaglutide and Semaglutide, which are medications used for type-2 diabetes. Studies regarding the effects and association of dulaglutide and Semaglutide to cholelithiasis and autoimmune-like hepatitis are very limited. This case report shows a possible association of these drugs with developing autoimmune-like hepatitis and cholelithiasis.
References
2. Collins L, Costello RA: Glucagon-Like Peptide-1 Receptor Agonists . 2023 Jan 13,
3. Perez-Montes DE Oca A, Pellitero S, Puig-Domingo M: Obesity and GLP-1. Minerva Endocrinol. 2021 Jun, 46:168-176. 10.23736/s2724-6507.20.03369-6
4. Grunberger G, Chang A, Garcia Soria G, Botros FT, Bsharat R, Milicevic Z: Monotherapy with the once- weekly GLP-1 analogue dulaglutide for 12 weeks in patients with Type 2 diabetes: dose-dependent effects on glycaemic control in a randomized, double-blind, placebo-controlled study. Diabet. Med. 2012 July, 29:1260-1267. 10.1111/j.1464-5491.2012.03745.x
5. Mirabelli M, Chiefari E, Tocci V, et al.: Clinical effectiveness and safety of once-weekly GLP-1 receptor agonist dulaglutide as add-on to metformin or metformin plus insulin secretagogues in obesity and type 2 diabetes. J. Clin. Med. 2021, 10:985. 10.3390/jcm10050985
6. Liyun He, Jialu Wang, Fan Ping, et al.: Association of Glucagon-Like Peptide-1 Receptor Agonist Use With Risk of Gallbladder and Biliary Diseases: A Systematic Review and Meta-analysis of Randomized Clinical Trials . JAMA Intern Med . 2022 March , 182:513-519. 10.1001/jamainternmed.2022.0338
7. Nreu B, Dicembrini I, Tinti F, Mannucci E, Monami M : Cholelithiasis in patients treated with Glucagon- Like Peptide-1 Receptor: An updated meta-analysis of randomized controlled trials. Diabetes Res Clin Pract. 2020 Mar, 161:108087. 10.1016/j.diabres.2020.108087
8. Di Ciaula A, Garruti G, Wang DQ, Portincasa P: Cholecystectomy and risk of metabolic syndrome. Eur J Intern Med. 2018 Jul, 53:3-11. 10.1016/j.ejim.2018.04.019
9. Czaja AJ: Drug-induced autoimmune-like hepatitis . Dig Dis Sci. 2011 Apr, 56:958-76. 10.1007/s10620-011- 1611-4
10. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet] . National Institute of Diabetes and Digestive and Kidney Diseases. 2012,
11. Björnsson ES, Medina-Caliz I, Andrade RJ, Lucena MI: Setting up criteria for drug-induced autoimmune-like hepatitis through a systematic analysis of published reports. Hepatol Commun. 2022 Aug, 6:1895-1909. 10.1002/hep4.1959
12. Sebode M, Schulz L, Lohse AW: Autoimmune(-Like)" Drug and Herb Induced Liver Injury: New Insights into Molecular Pathogenesis. Int J Mol Sci. 2017 Sep, 18(9):1954. 10.3390/ijms18091954
13. Parvataneni S, Ramachandran R, Then E, Grantham T: An Exceedingly Rare Case of Liraglutide-Induced Liver Injury. Case Rep Gastrointest Med. 2021 Aug, 23:6306149. 10.1155/2021/6306149
14. Musana K, Yale SH: John Benjamin Murphy (1857 - 1916) . Clin Med Res. 2005 May, 3:110-2. 10.3121/cmr.3.2.110
15. Reuben A, Koch DG, Lee WM: Drug-induced acute liver failure: results of a U.S. multicenter, prospective study. Hepatology. 2010 Dec, 52:2065-76. 10.1002/hep.23937
16. Dong YH, Wu JH, Chang CH, Lin JW, Wu LC, Toh S: Association between glucagon-like peptide-1 receptor agonists and biliary-related diseases in patients with type 2 diabetes: A nationwide cohort study. Pharmacotherapy. 2022 Jun, 42:483-494. 10.1002/phar.2688
17. Buse JB, Garber A, Rosenstock J, et al.: Liraglutide treatment is associated with a low frequency and magnitude of antibody formation with no apparent impact on glycemic response or increased frequency of adverse events: results from the Liraglutide Effect and Action in Diabetes (LEAD) trials. J Clin Endocrinol Metab. 2011 Jun, 96:1695-702. 10.1210/jc.2010-2822
18. Gilbert Lau MBBS: Iatrogenic Injury: A Forensic Perspective . Forensic Pathology Reviews. 2005, 3:351-439.
19. Czaja AJ: Rapidity of treatment response and outcome in type 1 autoimmune hepatitis . J Hepatol. 2009 Jul, 51:161-7. 10.1016/j.jhep.2009.02.026
20. Neahusan, Emma BS; Williams, Carson BS; Lee, Melissa MS, DO; Sadowski, Brett MD: Autoimmune Hepatitis-like Drug Injury of the Liver Associated with the Glucagon-like Peptide 1 (GLP-1) Agonist Dulaglutide. Am J Gastroenterol. October 2021, 116:S1189. 10.14309/01.ajg.0000785004.17193.b9
21. Kern, Emily MD; VanWagner, Lisa MD, MS; Rinella, Mary MD, FACG: Drug-induced Liver Injury Associated with the Glucagon-like Peptide 1 (GLP-1) Agonist Liraglutide. Am J Gastroenterol. October 2013, 108:S335- S336.
22. Patel AV, Jotwani PM, Lee TP: Drug-Induced Liver Injury Due to Dulaglutide Use . Am J Ther. 2019 Sep/Oct, 26(5):e620-e622. 10.1097/mjt.0000000000000826
23. Enslin, Sarah PA1; Bartell, Nicholas MD1; Kaul, Vivek MD, FACG2: The First Reported Case of Drug-Induced Liver Injury Caused by Semaglutide.. Am J Gastroenterol. October 2021, 116:S1141. 10.14309/01.ajg.0000784440.97741.d2
Article Sidebar
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All articles published in JPTCP are licensed under Copyright Creative Commons Attribution-NonCommercial 4.0 International License.
Khalid M. Alghamdi
Internal Medicine/ Gastroenterology, King Fahad General Hospital, Jeddah, KSA
Hassan A. Hifni
General Surgery, King Fahad General Hospital, Jeddah, KSA
Mohammed J. Almatrafi
Gastroenterology, King Abdullah Medical City, Makkah, KSA
Lama W. Attar
Medicine and Surgery, King Abdulaziz University Faculty of Medicine, Jeddah, KSA
Amal S. Alsulami
Medicine and Surgery, King Abdulaziz University Faculty of Medicine, Jeddah, KS
Bashayer H. Shalabi
Medicine and Surgery, King Abdulaziz University Faculty of Medicine, Jeddah, KSA
Afnan S. Agashami
Medicine and Surgery, King Saud Bin Abdulaziz University for Health Sciences College of Medicine, Jeddah, KSA